Gilead backs away from antiviral monopoly after criticism

Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Indian NGO wants Gilead patents cancelled

15 April 2020 An association representing Indian cancer patients has asked the country’s government to cancel Gilead Sciences’ patents on remdesivir, the experimental antiviral which is hoped can be used to treat coronavirus.

Big Pharma

Gilead told to waive remdesivir patent rights

2 April 2020 Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.

Big Pharma

Gilead expands special access to potential COVID-19 drug

31 March 2020 Gilead Sciences says it is expanding access to its experimental antiviral remdesivir for treatment of COVID-19, albeit on a limited basis.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Gilead backs away from antiviral monopoly after criticism

More on this story

Editor's picks

Editor's picks

More features